Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Galectin-3 (Gal-3) is a β-galactoside binding protein associated with many disease pathologies, including chronic inflammation and fibrogenesis. It has been implicated in the disease severity of NASH, although its precise role is unknown. Inhibition of Gal-3 has shown to improve and prevent fibrosis progression and has now reached phase III clinical trial in NASH patients. AREAS COVERED: This discusses the role of Gal-3 in NASH. It brings together the current findings of Gal-3 in NASH and hepatic fibrosis by analyzing recent data from animal model studies and clinical trials. EXPERT OPINION: Gal-3 inhibitors, in particular, Belapectin (GR-MD-02), have shown promising results for NASH with advanced fibrosis. In a phase 2 trial, Belapectin did not meet the primary endpoint. However, a sub-analysis of Belapectin among a separate group of patients without esophageal varices showed 2 mg/kg of GR-MD-02 reduced HVPG and the development of new varices. A subsequent study is under way, aiming to replicate the positive findings in phase 2 and demonstrate greater efficacy. If Belapectin is shown to be effective, it will be coupled with other drugs that target steatohepatitis to maximize efficacy and disease reversal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar to cytokines, galectin 3 is secreted by macrophages upon liver injury in NASH and has profibrotic activity.102”
From An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH (2023) · cites this paper as [102]
Citations
Cites
Byrne, C. D., & Targher, G. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.12.012 · Cited by 3,042 · cited 1×
“[2,3], and it is not only a liver-related disorder, but clinical evidence describes it as a multisystem disorder [4,5].”
BackgroundAngulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · cited 1×
“tions, such as ascites, hepatic encephalopathy, variceal hemorrhage, end-stage liver disease, hepatocellular carcinoma (HCC), and increase liver-related and all-cause mortality [7].”
BackgroundSingle-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0901-9 · Cited by 2,614
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“liraglutide, semaglutide) [42,43], acetyl-CoA carboxylase inhibition (i.”
Galectin-3: An open-ended story
Dumic, J., Dabelic, S., & Flögel, M. (2006) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2005.12.020 · Cited by 1,169 · cited 1×
“and extracellular level allows it to exert its effects by binding to numerous partners and signaling molecules [22,23].”
BackgroundZhou, Y., Song, W. M., Andhey, P. S., Swain, A., Levy, T., Miller, K. R., Poliani, P. L., Cominelli, M., Grover, S., Gilfillan, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0695-9 · Cited by 1,150
De Biasi, S., Meschiari, M., Gibellini, L., Bellinazzi, C., Borella, R., Fidanza, L., Gozzi, L., Iannone, A., Lo Tartaro, D., Mattioli, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17292-4 · Cited by 789
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772 · cited 1×
“Some of those include the NAFLD fibrosis score (NFS) and the FIB-4 score [10].”
BackgroundGalectin-3 regulates myofibroblast activation and hepatic fibrosis
Henderson, N. C., Mackinnon, A. C., Farnworth, S. L., Poirier, F., Russo, F. P., Iredale, J. P., Haslett, C., Simpson, K. J., & Sethi, T. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0511167103 · Cited by 625 · cited 3×
“fibrosis, with a marked expression in the periphery of inflamed damaged areas [27].”
BackgroundResultInfluentialExtrahepatic complications of nonalcoholic fatty liver disease
Armstrong, M. J., Adams, L. A., Canbay, A., & Syn, W.-K. (2014) · Hepatology · doi:10.1002/hep.26717 · Cited by 600
Research works printed but not linked: 2
- Petit JM, 2017, J Clin Endocrinol Metab, 102, 407
- Dong R, 2018, Int J Mol Med, 41, 599
Cited by
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 359
An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH
Tacke, F., Puengel, T., Loomba, R., & Friedman, S. L. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.038 · Cited by 321
Glycoconjugates: Synthesis, Functional Studies, and Therapeutic Developments
Shivatare, S. S., Shivatare, V. S., & Wong, C.-H. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c01032 · Cited by 257
Macrophage functional diversity in NAFLD — more than inflammation
Barreby, E., Chen, P., & Aouadi, M. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00675-6 · Cited by 247
Chen, Y., Wang, W., Morgan, M. P., Robson, T., & Annett, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1148934 · Cited by 76
Metadata
- Authors
- Al Attar, A., Antaramian, A., & Noureddin, M.
- Affiliations
- Karsh Division of Gastroenterology and Hepatology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Cedars-Sinai Medical Center (US)
- Corresponding author
- Noureddin, Mazen
- ORCID
- Noureddin, Mazen
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2021-03-02
- Volume
- 14
- Issue
- 4
- Pages
- 457-464
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W3130635956
- Cited by
- 47
- References
- 71
- Citations by year
- 2026: 2 · 2025: 12 · 2024: 11 · 2023: 9 · 2022: 12 · 2021: 1
- FWCI
- 1.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Galectins and Cancer Biology
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- galectin-3, galectin-3 inhibitors, nonalcoholic steatohepatitis, liver fibrosis, esophageal varices, portal hypertension, chronic inflammation, combination therapy
- MeSH terms
- Animals, Blood Proteins, Disease Models, Animal, Humans, Liver Cirrhosis, Pectins, Severity of Illness Index, Disease Progression, Galectins, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. https://app.cochat.ai/papers/10.1080/17512433.2021.1894127
- The paper
- Al Attar, A., Antaramian, A., & Noureddin, M. (2021). Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2021.1894127
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.